Partnered Program
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Pre-clinicalActive
Key Facts
Indication
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase
Pre-clinical
Status
Active
Company
About Cellarity
Cellarity is a private, AI-driven biotech founded in 2017 that is shifting the drug discovery paradigm from single-target to cell-state-focused therapeutics. Its core technology combines high-dimensional single-cell data with AI models to identify novel biological pathways and design oral compounds that correct dysfunctional cellular networks. The company has advanced its first candidate, CLY-124 for sickle cell disease, into clinical development and has established a strategic partnership with Novo Nordisk in metabolic disease, validating its platform's potential.
View full company profileTherapeutic Areas
Other Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM831 (MK-3655) | NGM Biopharmaceuticals | Phase 2b |
| Pegozafermin (BIO89-100) | 89bio | Phase 3 |
| Icosabutate | NorthSea Therapeutics | Phase 3 |
| Oxy210 | MAX BioPharma | Preclinical |
| NA-941 | Biomed | Phase 2A |
| PRO-MSH-001 | ProdIgY Biotech | Discovery |
| Undisclosed MASH Program | Syndya Therapeutics | Discovery |
| Lanifibranor | Hepalys | Phase 1 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| ION224 (IONIS-DGAT2Rx) | Ionis Pharmaceuticals | Phase 2b |
| ALG-055009 | Aligos Therapeutics | Phase 2 |
| CM-101 | Chemomab Therapeutics | Phase 2a |